Ketorolac tromethamine 0.4% to relieve eye pain and inflammation following cataract extraction and keratorefractive surgery

Abstract

Ketorolac tromethamine ophthalmic solution, a NSAID, demonstrated analgesic activity when administered systemically. The original 0.5% formulation was shown to reduce inflammation and pain, as well as general discomfort after cataract and keratorefractive surgery. A reformulation that contains 20% less active ingredient than the original was approved for the reduction of ocular pain and burning/stinging following corneal refractive surgery. Ketorolac tromethamine 0.4% is as effective as ketorolac tromethamine 0.5% to control inflammation after cataract surgery (including prevention of cystoid macular edema) as shown in different clinical trials. Comparisons to other NSAIDs for pain control after keratorefractive procedures, such as laser-assisted in situ keratomileusis and photorefractive keratectomy, have also been reported. The purpose of this study was to review the action of ketorolac tromethamine 0.4% in the relief of eye pain and inflammation after cataract extraction and keratorefractive surgery.

Keywords::

• eye
• inflammation
• ketorolac
• NSAID
• ocular
• pain

Financial & competing interests disclosure

The authors have been supported in part by NIH/NEI EY-014793; and an unrestricted grant to MUSC-SEI from Research to Prevent Blindness, New York, NY, USA. The authors have no financial or proprietary interest in any product mentioned herein. Kerry D Solomon, MD, is a consultant for Alcon Laboratories and Allergan, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.